[go: up one dir, main page]

CL2012001650A1 - Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab. - Google Patents

Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab.

Info

Publication number
CL2012001650A1
CL2012001650A1 CL2012001650A CL2012001650A CL2012001650A1 CL 2012001650 A1 CL2012001650 A1 CL 2012001650A1 CL 2012001650 A CL2012001650 A CL 2012001650A CL 2012001650 A CL2012001650 A CL 2012001650A CL 2012001650 A1 CL2012001650 A1 CL 2012001650A1
Authority
CL
Chile
Prior art keywords
gpvi
fab fragment
antibody fab
prevent
polynucleotide
Prior art date
Application number
CL2012001650A
Other languages
English (en)
Inventor
Beatrice Cameron
Nicolas Baurin
Francis Blanche
Carsten Corvey
Tarikm Dabdoubi
Christian Engel
Peter Florian
Foc
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09306283A external-priority patent/EP2336188A1/en
Priority claimed from EP10305660A external-priority patent/EP2397495A1/en
Priority claimed from EP10305721A external-priority patent/EP2402371A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2012001650A1 publication Critical patent/CL2012001650A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Fragmento Fab de anticuerpo que se une específicamente a la glicoproteína VI (GPVI) humana e induce un fenotipo de reducción de GPVI; composición farmacéutica que comprende dichos fragmentos Fab de anticuerpo anti-GPVI; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento Fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del C-terminal de dicho fragmento Fab.
CL2012001650A 2009-12-18 2012-06-18 Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab. CL2012001650A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306283A EP2336188A1 (en) 2009-12-18 2009-12-18 Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP10305660A EP2397495A1 (en) 2010-06-21 2010-06-21 Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP10305721A EP2402371A1 (en) 2010-07-01 2010-07-01 Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof

Publications (1)

Publication Number Publication Date
CL2012001650A1 true CL2012001650A1 (es) 2012-12-14

Family

ID=44060924

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001650A CL2012001650A1 (es) 2009-12-18 2012-06-18 Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab.

Country Status (30)

Country Link
US (2) US8852593B2 (es)
EP (2) EP2513147B1 (es)
JP (1) JP5843783B2 (es)
KR (1) KR20120102125A (es)
CN (1) CN102725309B (es)
AR (1) AR079645A1 (es)
AU (1) AU2010331807B2 (es)
BR (1) BR112012014975A2 (es)
CA (1) CA2784498A1 (es)
CL (1) CL2012001650A1 (es)
CY (1) CY1118389T1 (es)
DK (1) DK2513147T3 (es)
EA (1) EA201290525A1 (es)
ES (1) ES2596254T3 (es)
HK (1) HK1216537A1 (es)
HR (1) HRP20161298T1 (es)
HU (1) HUE029824T2 (es)
IL (1) IL220447A0 (es)
LT (1) LT2513147T (es)
MA (1) MA33930B1 (es)
MX (2) MX2012007153A (es)
PH (1) PH12012501219A1 (es)
PL (1) PL2513147T3 (es)
PT (1) PT2513147T (es)
SG (2) SG181707A1 (es)
SI (1) SI2513147T1 (es)
TW (1) TW201132759A (es)
UY (1) UY33115A (es)
WO (1) WO2011073954A2 (es)
ZA (1) ZA201204421B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
TW201132759A (en) * 2009-12-18 2011-10-01 Sanofi Aventis Novel antagonist antibodies and their FaB fragments against GPVI and uses thereof
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
EP2944653A1 (en) * 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
IN2014CN00414A (es) 2011-06-23 2015-04-03 Ablynx Nv
CN108659121A (zh) * 2011-06-23 2018-10-16 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
EP4350345A3 (en) * 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
ES2813432T3 (es) * 2011-08-17 2021-03-23 Glaxo Group Ltd Proteínas y péptidos modificados
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20140161796A1 (en) * 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
CN103396492A (zh) * 2013-08-06 2013-11-20 安徽新标志科技有限公司 抗人血小板胶原蛋白受体的人源性单克隆抗体片段及其应用
EP4091628A1 (en) 2015-08-05 2022-11-23 Acticor Biotech Novel anti-human gpvi antibodies and uses thereof
EP3538552B1 (en) 2016-11-14 2023-09-13 MorphoSys AG Fab molecules with a rodent hinge region and a non-rodent ch1 region
AU2018214222C1 (en) 2017-02-03 2021-08-05 Acticor Biotech Inhibition of platelet aggregation using anti-human GPVI antibodies
IL278323B2 (en) * 2018-05-16 2025-05-01 Morphosys Ag Antibodies directed against glycoprotein IV
GB202020602D0 (en) * 2020-12-24 2021-02-10 Univ Birmingham Nanobody
WO2022257106A1 (zh) * 2021-06-11 2022-12-15 江苏丰华生物制药有限公司 一种人源化抗人GPVI单克隆抗体Fab片段及其应用
WO2023133470A2 (en) * 2022-01-07 2023-07-13 BioLegend, Inc. Tmprss2 binding antibodies and antigen binding fragments thereof
CN115991780B (zh) * 2022-12-29 2025-06-10 盖普思药业(重庆)有限公司 一种抗人血小板胶原蛋白受体gp-vi抗体或其抗原结合片段及其应用
EP4431526A1 (en) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498237B2 (en) 1989-08-07 2002-12-24 Peptech Limited Tumor necrosis factor antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9109478D0 (en) * 1991-05-02 1991-06-26 Therapeutic Antibodies Inc Antivenoms
US7062219B2 (en) * 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
WO2001032688A1 (en) * 1999-10-29 2001-05-10 Rutgers, The State University Of New Jersey Renilla reniformis green fluorescent protein
US20030049701A1 (en) * 2000-09-29 2003-03-13 Muraca Patrick J. Oncology tissue microarrays
EP1224942A1 (en) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
GB0130543D0 (en) * 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0511590D0 (en) * 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
EP1369128A1 (en) * 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
EP1538165A1 (en) * 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
WO2005007800A2 (ja) * 2003-07-18 2005-01-27 Mochida Pharm Co Ltd 抗血小板膜糖蛋白質ⅵモノクローナル抗体
JP4734319B2 (ja) 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
ES2389047T3 (es) * 2004-04-29 2012-10-22 Otsuka Pharmaceutical Co., Ltd. Anticuerpos específicos contra la glicoproteína VI y procedimientos de producción de estos anticuerpos
EP1824979A2 (en) * 2004-12-10 2007-08-29 Trigen GmbH Methods, products and uses involving platelets and/or the vasculature
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
WO2006118350A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
JPWO2007091719A1 (ja) * 2006-02-07 2009-07-02 持田製薬株式会社 抗ｇｐｖｉ抗体の併用療法及び新規医薬用途
US8323905B2 (en) * 2006-03-31 2012-12-04 Mochida Pharmaceutical Co., Ltd. Methods of detection GPVI
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
DK2195023T3 (en) 2007-08-29 2018-06-18 Sanofi Sa HUMANIZED ANTI-CXCR5 ANTIBODIES, DERIVATIVES THEREOF AND THEIR USE
CN101874107A (zh) * 2007-10-31 2010-10-27 大塚制药株式会社 糖蛋白ⅵ(gpvi)抑制剂的用途
EP2362783A2 (en) * 2008-10-31 2011-09-07 Biogen Idec MA Inc. Light targeting molecules and uses thereof
TW201132759A (en) * 2009-12-18 2011-10-01 Sanofi Aventis Novel antagonist antibodies and their FaB fragments against GPVI and uses thereof

Also Published As

Publication number Publication date
MX347613B (es) 2017-05-04
BR112012014975A2 (pt) 2019-09-24
PL2513147T3 (pl) 2017-08-31
LT2513147T (lt) 2016-10-25
CA2784498A1 (en) 2011-06-23
SI2513147T1 (sl) 2016-11-30
EP2513147B1 (en) 2016-07-20
ES2596254T3 (es) 2017-01-05
EP2933269A1 (en) 2015-10-21
EP2513147A2 (en) 2012-10-24
AR079645A1 (es) 2012-02-08
WO2011073954A2 (en) 2011-06-23
AU2010331807A1 (en) 2012-07-12
CN102725309B (zh) 2016-01-06
MX2012007153A (es) 2012-07-03
AU2010331807B2 (en) 2016-08-04
MA33930B1 (fr) 2013-01-02
JP2013514077A (ja) 2013-04-25
HUE029824T2 (en) 2017-04-28
US20120244152A1 (en) 2012-09-27
UY33115A (es) 2011-07-29
SG181707A1 (en) 2012-07-30
CY1118389T1 (el) 2017-06-28
EA201290525A1 (ru) 2013-01-30
WO2011073954A3 (en) 2012-03-08
PT2513147T (pt) 2016-10-11
JP5843783B2 (ja) 2016-01-13
TW201132759A (en) 2011-10-01
ZA201204421B (en) 2013-09-25
PH12012501219A1 (en) 2017-08-23
HRP20161298T1 (hr) 2016-11-18
SG10201405259PA (en) 2014-10-30
KR20120102125A (ko) 2012-09-17
CN102725309A (zh) 2012-10-10
HK1216537A1 (en) 2016-11-18
US8852593B2 (en) 2014-10-07
DK2513147T3 (en) 2016-10-24
US20150098939A1 (en) 2015-04-09
US9441040B2 (en) 2016-09-13
IL220447A0 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
CL2012001650A1 (es) Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab.
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
AR081750A1 (es) Anticuerpos anti-cd40
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2012001540A1 (es) Anticuerpos o fragmento de union a antigeno que antagoniza la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrogeno y progestina.
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
GT201200132A (es) Antagonistas il-17a
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
CL2008002952A1 (es) Proteina de union a antigenos que se une a interleucina-23 humana (il-23); composicion farmaceutica que la comprende; y su uso para tratar inflamaciones mediadas por el sistema inmunitario
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
CR10298A (es) Metodos y composiciones para antagonismo de rage
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
MX2017001597A (es) Anticuerpos anti-pd-l1.
CL2017001461A1 (es) Composiciones y métodos para anticuerpos que se marcan bmp6
GT201300233A (es) Receptores de celulas t similares a anticuerpos especificos para un peptido wt1 presentado por hla-a2
GT201400049A (es) "anticuerpos a pcsk9 y usos de los mismo"
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
CO6440515A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
SG178886A1 (en) Humanized anti-cdcp1 antibodies
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
UA106529C2 (uk) Гуманізоване антитіло до cxcr4 для лікування раку